Best clinical response to single-agent brentuximab vedotin
| . | DLBCL . | Other B-cell . | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Refractory (n = 39) . | Relapsed (n = 8) . | Total (n = 48)* . | Total (n = 19)† . | |||||||||
| No. . | % . | 95% CI‡ . | No. . | % . | 95% CI‡ . | No. . | % . | 95% CI‡ . | No. . | % . | 95% CI‡ . | |
| Objective response rate | 17 | 44 | 27.8 to 60.4 | 3 | 38 | 8.5 to 75.5 | 21 | 44 | 29.5 to 58.8 | 5 | 26 | 9.1 to 51.2 |
| Best clinical response§ | ||||||||||||
| CR | 6 | 15 | 2 | 25 | 8 | 17 | 3 | 16 | ||||
| PR | 11 | 28 | 1 | 13 | 13 | 27* | 2 | 11 | ||||
| SD | 8 | 21 | 3 | 38 | 11 | 23 | 7 | 37 | ||||
| PD | 14 | 36 | 2 | 25 | 16 | 33 | 6 | 32 | ||||
| Disease control rate|| | 25 | 64 | 6 | 75 | 32 | 67 | 12 | 63 | ||||
| . | DLBCL . | Other B-cell . | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Refractory (n = 39) . | Relapsed (n = 8) . | Total (n = 48)* . | Total (n = 19)† . | |||||||||
| No. . | % . | 95% CI‡ . | No. . | % . | 95% CI‡ . | No. . | % . | 95% CI‡ . | No. . | % . | 95% CI‡ . | |
| Objective response rate | 17 | 44 | 27.8 to 60.4 | 3 | 38 | 8.5 to 75.5 | 21 | 44 | 29.5 to 58.8 | 5 | 26 | 9.1 to 51.2 |
| Best clinical response§ | ||||||||||||
| CR | 6 | 15 | 2 | 25 | 8 | 17 | 3 | 16 | ||||
| PR | 11 | 28 | 1 | 13 | 13 | 27* | 2 | 11 | ||||
| SD | 8 | 21 | 3 | 38 | 11 | 23 | 7 | 37 | ||||
| PD | 14 | 36 | 2 | 25 | 16 | 33 | 6 | 32 | ||||
| Disease control rate|| | 25 | 64 | 6 | 75 | 32 | 67 | 12 | 63 | ||||
One patient was missing disease status, but had a response assessment and was included in the efficacy analysis.
One response was determined to be not evaluable because the patient had no measureable baseline lesions.
Two-sided 95% exact confidence intervals (CIs).
Per Cheson, as assessed by the investigator.
CR + PR + SD.